Jiaojuan He

A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin

Pablo Lapuerta, Silvia Urbina, Jiaojuan He, Alyssa Wittle et autres

YG1699 is a novel inhibitor of sodium‐glucose cotransporter 1 (SGLT1) and SGLT2. This double‐blind, 3‐way crossover trial compared YG1699 to dapagliflozin as an adjunct to insulin in people with type 1 diabetes (T1D) on insulin pump therapy. Treatment periods included four mixed …

us (code pays fourni par la source)

882-P: Effects of YG1699 and Sotagliflozin on Intestinal Glucose Absorption and GLP-1 in Mice

JACKY LI, ROGER W. XU, Jiaojuan He, Pablo Lapuerta

Background and Aims: YG1699, a dual inhibitor of SGLT1 and SGLT2, recently showed greater glucose reduction than dapagliflozin in patients with type 1 diabetes. This study examined whether YG1699 provides gastrointestinal SGLT1 inhibition. Materials and Methods: Male BALB/c mice (n=105) were randomly …

Relation between changes of TXB2 and PGF1 alpha and the severity of the disease and pathological lesions in cases of severe icteric hepatitis.

C B Wang, Jiaojuan He, Jie Xu, Ziying Lei et autres

Clinically, 32 cases of intrahepatic cholestasis and 30 cases of severe chronic hepatitis with a bilirubin level higher than 171 mumol/L were studied. The results showed that bilirubin was 420 mumol/L in the first group, and 480 mumol/L in the second group …

cn (code pays fourni par la source)